Tabula Rasa HealthCare (DB:43T) - Cotización, noticias y análisis

Resumen de acción 43T

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States.

43T fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	1/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 13.23%

Análisis de riesgos

Patrimonio neto negativo

Los accionistas han sido diluidos en el último año

Volatilidad del precio de la acción en los últimos 3 meses

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Tabula Rasa HealthCare, Inc.

Nexus

XTRA:NXU

€935.7m

DocCheck

XTRA:AJ91

€45.9m

MeVis Medical Solutions

XTRA:M3V

€46.2m

CompuGroup Medical SE KGaA

XTRA:COP

€1.5b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Tabula Rasa HealthCare
Historical stock prices
Current Share Price	US$9.60
52 Week High	US$9.85
52 Week Low	US$3.12
Beta	1.58
1 Month Change	-0.52%
3 Month Change	36.17%
1 Year Change	177.46%
3 Year Change	-66.20%
5 Year Change	-85.54%
Change since IPO	-22.79%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	43T	DE Healthcare Services	Mercado DE
7D	-0.5%	-3.9%	-2.0%
1Y	177.5%	-24.7%	-0.3%

Rentabilidad vs. Industria: 43T superó al sector German Healthcare Services , que obtuvo un rendimiento del -10.2% el año pasado.

Rentabilidad vs. Mercado: 43T superó al mercado German, que obtuvo un rendimiento del 5.9% el año pasado.

Volatilidad de los precios

Is 43T's price volatile compared to industry and market?
43T volatility
43T Average Weekly Movement	8.4%
Healthcare Services Industry Average Movement	4.1%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: 43Tha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: 43T(8%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de German.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2009	1,027	Brian Adams	www.tabularasahealthcare.com

Resumen de fundamentos de Tabula Rasa HealthCare, Inc.

¿Cómo se comparan los beneficios e ingresos de Tabula Rasa HealthCare con su capitalización de mercado?
Estadísticas fundamentales de 43T
Capitalización bursátil	€264.89m
Beneficios(TTM)	-€56.95m
Ingresos (TTM)	€315.33m

0.8x

Ratio precio-ventas (PS)

-4.7x

Ratio precio-beneficio (PE)

¿Está 43T sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 43T
Ingresos	US$338.12m
Coste de los ingresos	US$258.28m
Beneficio bruto	US$79.84m
Otros gastos	US$140.91m
Beneficios	-US$61.07m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.26
Margen bruto	23.61%
Margen de beneficio neto	-18.06%
Ratio deuda/patrimonio	-418.7%

¿Cómo se ha desempeñado 43T a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 43T

Recompensas

Análisis de riesgos

Competidores de Tabula Rasa HealthCare, Inc.

XTRA:NXU

€935.7m

XTRA:AJ91

€45.9m

XTRA:M3V

€46.2m

XTRA:COP

€1.5b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

New major risk - Share price stability

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

Second quarter 2023 earnings released: US$0.38 loss per share (vs US$0.53 loss in 2Q 2022)

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Recent updates

Tabula Rasa HealthCare, Inc. Files Form 15

Exact Care Pharmacy, LLC completed the acquisition of Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others.

New major risk - Share price stability

Exact Care Pharmacy, LLC entered into a definitive agreement to acquire Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC) from Indaba Capital Fund, L.P, managed by Indaba Capital Management, L.P. and others for approximately $320 million.

Second quarter 2023 earnings released: US$0.38 loss per share (vs US$0.53 loss in 2Q 2022)

Tabula Rasa Healthcare, Inc. Appoints Michael Bruno as Chief Accounting Officer

Tabula Rasa HealthCare, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Tabula Rasa Healthcare, Inc. Provides Revenue Guidance for the Second Quarter Ending June 30, 2023 and Full Year Ending December 31, 2023

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.85 loss in 1Q 2022)

Full year 2022 earnings released: US$3.18 loss per share (vs US$3.39 loss in FY 2021)

Tabula Rasa Healthcare, Inc. Revises Preliminary Revenue Guidance for the Fourth Quarter 2022

Insufficient new directors

Third quarter 2022 earnings released: US$1.06 loss per share (vs US$0.73 loss in 3Q 2021)

Tabula Rasa HealthCare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ending December 31, 2022

Tabula Rasa Healthcare, Inc. Names April Gill Chief Commercial Officer

Tabula Rasa HealthCare, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Tabula Rasa Healthcare, Inc. Announces Board Changes

Tabula Rasa Healthcare, Inc. Announces Executive Changes

Tabula Rasa HealthCare, Inc. announces New Study Demonstrates Benefit of Advanced Decision Support in Driving Pharmacist Recommendations to Reduce Medication Risk

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Indaba Capital Management L.P. Issues Letter to Tabula Rasa HealthCare Inc’s Independent Directors

Second quarter 2022 earnings released: US$0.53 loss per share (vs US$0.91 loss in 2Q 2021)

Indaba Capital Sends Letter to Demand for Inspection of Books and Records of Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Indaba Capital Management L P Sends a Letter to Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare Revises Revenue Guidance for the Second Quarter Ended June 30, 2022

First quarter 2022 earnings released: US$0.85 loss per share (vs US$0.85 loss in 1Q 2021)

Insufficient new directors

Tabula Rasa HealthCare, Inc. to Report Q1, 2022 Results on May 05, 2022

Independent Director recently bought €53k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Tom Cancro Joins Tabula Rasa Healthcare, Inc. as Chief Financial Officer

Now 20% undervalued after recent price drop

Tabula Rasa HealthCare, Inc. to Report Q4, 2021 Results on Feb 24, 2022

An unknown buyer agreed to acquire DoseMeRx Solution of Tabula Rasa HealthCare, Inc.

Co-President recently sold €84k worth of stock

Insufficient new directors

Tabula Rasa Healthcare, Inc. Announces Results of Two Peer-Reviewed Studies That Explore Potential for Drug Interactions Among Those Who Use Opioids and Take Multiple Medications

Insufficient new directors

Co-Founder recently sold €2.5m worth of stock

Third quarter 2021 earnings released: US$0.73 loss per share (vs US$0.99 loss in 3Q 2020)

Tabula Rasa and Hesperos Receive $1.9 Million National Institutes of Health Award for Research Focused on Preventable Drug-Induced Alzheimer's Disease

Chief Operating Officer recently sold €76k worth of stock

Tabula Rasa Healthcare, Inc. Provides Earnings Guidance for the Quarter Ending September 30, 2021 and Year Ending December 31, 2021

Second quarter 2021 earnings released: US$0.91 loss per share (vs US$0.66 loss in 2Q 2020)

Tabula Rasa HealthCare, Inc. Enhances PrescribeWellness Software with MedWise Risk Level™

Tabula Rasa Healthcare, Inc. Announces Results of Simulation-Based Clinical Study which Demonstrates its MedWise® Medication Risk Score can be Used to Assess Drug Safety without Exposing Real People to Actual Harm

First quarter 2021 earnings released: US$0.85 loss per share (vs US$0.68 loss in 1Q 2020)

Tabula Rasa Healthcare, Inc. Provides Earnings Guidance for the Second Quarter and Reiterating Earnings Guidance for the Year 2021

Tabula Rasa Healthcare, Inc. Signs Agreement with Multiple State Pharmacy Associations to Bring Medication Risk Mitigation Technology to Members

New 90-day low: €28.80

Revenue beats expectations

Full year 2020 earnings released: US$3.71 loss per share (vs US$1.57 loss in FY 2019)

Tabula Rasa HealthCare, Inc. and ASHP Partner to Facilitate Use of MedWise™ Software, Improve the Safe Use of Medications in Health Systems

Tabula Rasa HealthCare to Provide Innovative Medication Risk Mitigation Technology to National Primary Care Network MDVIP

PrimeRx™ and Tabula Rasa HealthCare Now Offer Integration Technology for Automated COVID-19 Vaccine Reporting

Tabula Rasa HealthCare, Inc. to Report Q4, 2020 Results on Feb 23, 2021

Tabula Rasa HealthCare, Inc. Deploys MedWise Risk Score™ Technology to PrescribeWellness Community Pharmacy Network

Tabula Rasa Healthcare Partners with RxResults to Provide Pharmacy Risk Management for Health Plans